Followers | 186 |
Posts | 10823 |
Boards Moderated | 4 |
Alias Born | 06/20/2022 |
![](https://investorshub.advfn.com/uicon/824868.png?cb=1719952235)
Tuesday, January 31, 2023 9:46:08 AM
![Bullish](/static/images/ih2-bull.png)
Recent CNTX News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/14/2024 11:50:14 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/14/2024 11:34:52 AM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 06/03/2024 04:15:21 AM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 05/31/2024 08:06:51 PM
- Form SC 13G - Statement of acquisition of beneficial ownership by individuals • Edgar (US Regulatory) • 05/24/2024 08:15:19 PM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 05/24/2024 11:31:07 AM
- Form SC 13G - Statement of acquisition of beneficial ownership by individuals • Edgar (US Regulatory) • 05/10/2024 08:00:06 PM
- Context Therapeutics Reports First Quarter 2024 Operating and Financial Results • GlobeNewswire Inc. • 05/08/2024 08:06:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/08/2024 08:03:39 PM
- Context Therapeutics Announces FDA Clearance of IND Application for a Phase 1 Clinical Trial of CTIM-76 • GlobeNewswire Inc. • 05/02/2024 11:31:53 AM
- Context Therapeutics Announces $100 Million Private Placement • GlobeNewswire Inc. • 05/02/2024 11:30:00 AM
- Context Therapeutics Submits IND Application to Evaluate CTIM-76 in Claudin 6-Positive Cancers • GlobeNewswire Inc. • 04/01/2024 11:30:00 AM
- Context Therapeutics Reports Full Year 2023 Operating and Financial Results • GlobeNewswire Inc. • 03/21/2024 11:43:24 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/06/2024 12:30:51 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/07/2024 09:24:50 PM
- Context Therapeutics Reports Third Quarter 2023 Operating and Financial Results • GlobeNewswire Inc. • 11/09/2023 09:15:51 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/09/2023 09:04:33 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2023 01:04:29 PM
- Context Therapeutics Announces Preclinical Data Demonstrating Differentiated and Active Profile of its Claudin 6-Targeted Bispecific Antibody CTIM-76 • GlobeNewswire Inc. • 10/31/2023 01:00:00 PM
- Context Therapeutics Announces Acceptance of Abstract to be Presented at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting • GlobeNewswire Inc. • 09/27/2023 01:00:00 PM
- Context Therapeutics Reports Second Quarter 2023 Operating and Financial Results • GlobeNewswire Inc. • 08/09/2023 08:10:56 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/09/2023 08:04:41 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/07/2023 12:11:05 PM
- Context Therapeutics to Participate in Two August 2023 Investor Conferences • GlobeNewswire Inc. • 08/01/2023 11:30:00 AM
Glidelogic Corp. Becomes TikTok Shop Partner, Opening a New Chapter in E-commerce Services • GDLG • Jul 5, 2024 7:09 AM
Freedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent • FHLD • Jul 3, 2024 9:00 AM
EWRC's 21 Moves Gaming Studios Moves to SONY Pictures Studios and Green Lights Development of a Third Upcoming Game • EWRC • Jul 2, 2024 8:00 AM
BNCM and DELEX Healthcare Group Announce Strategic Merger to Drive Expansion and Growth • BNCM • Jul 2, 2024 7:19 AM
NUBURU Announces Upcoming TV Interview Featuring CEO Brian Knaley on Fox Business, Bloomberg TV, and Newsmax TV as Sponsored Programming • BURU • Jul 1, 2024 1:57 PM
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM